Toll-like receptor-2/6 and toll-like receptor-9 agonists suppress viral replication but not airway hyperreactivity in guinea pigs

Matthew Drake, Scott E. Evans, Burton F. Dickey, Allison Fryer, David Jacoby

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Respiratory virus infections cause airway hyperreactivity (AHR). Preventative strategies for virus-induced AHR remain limited. Toll-like receptors (TLRs) have been suggested as a therapeutic target because of their central role in triggering antiviral immune responses. Previous studies showed that concurrent treatment with TLR2/6 and TLR9 agonists reduced lethality and the microbial burden in murine models of bacterial and viral pneumonia. This study investigated the effects of TLR2/6 and TLR9 agonist pretreatment on parainfluenza virus pneumonia and virus-induced AHR in guinea pigs in vivo. Synthetic TLR2/6 lipopeptide agonist Pam2CSK4 and Class C oligodeoxynucleotide TLR9 agonist ODN2395, administered in combination 24 hours before virus infection, significantly reduced viral replication in the lung. Despite a fivefold reduction in viral titers, concurrent TLR2/6 and TLR9 agonist pretreatment did not prevent virus-induced AHR or virus-induced inhibitory M2 muscarinic receptor dysfunction. Interestingly, the TLR agonists independently caused non-M2-dependent AHR. These data confirm the therapeutic antiviral potential of TLR agonists, while suggesting that virus inhibition may be insufficient to prevent virus-induced airway pathophysiology. Furthermore, TLR agonists independently cause AHR, albeit through a distinctly differentmechanismfrom that of parainfluenza virus.

Original languageEnglish (US)
Pages (from-to)790-796
Number of pages7
JournalAmerican Journal of Respiratory Cell and Molecular Biology
Volume48
Issue number6
DOIs
StatePublished - Jun 2013

Fingerprint

Toll-Like Receptor 6
Toll-Like Receptor 9
Toll-Like Receptor 2
Viruses
Guinea Pigs
Toll-Like Receptors
Paramyxoviridae Infections
Virus Diseases
Antiviral Agents
Viral Pneumonia
Muscarinic M2 Receptors
Bacterial Pneumonia
Oligodeoxyribonucleotides
Lipopeptides
Respiratory Tract Infections
Pneumonia
Cohort Studies

Keywords

  • Airway hyperreactivity
  • Muscarinic receptor
  • Parainfluenza virus
  • Toll-like receptor

ASJC Scopus subject areas

  • Cell Biology
  • Pulmonary and Respiratory Medicine
  • Molecular Biology
  • Clinical Biochemistry

Cite this

@article{213c22a33f724345b22a32cb49b24fc0,
title = "Toll-like receptor-2/6 and toll-like receptor-9 agonists suppress viral replication but not airway hyperreactivity in guinea pigs",
abstract = "Respiratory virus infections cause airway hyperreactivity (AHR). Preventative strategies for virus-induced AHR remain limited. Toll-like receptors (TLRs) have been suggested as a therapeutic target because of their central role in triggering antiviral immune responses. Previous studies showed that concurrent treatment with TLR2/6 and TLR9 agonists reduced lethality and the microbial burden in murine models of bacterial and viral pneumonia. This study investigated the effects of TLR2/6 and TLR9 agonist pretreatment on parainfluenza virus pneumonia and virus-induced AHR in guinea pigs in vivo. Synthetic TLR2/6 lipopeptide agonist Pam2CSK4 and Class C oligodeoxynucleotide TLR9 agonist ODN2395, administered in combination 24 hours before virus infection, significantly reduced viral replication in the lung. Despite a fivefold reduction in viral titers, concurrent TLR2/6 and TLR9 agonist pretreatment did not prevent virus-induced AHR or virus-induced inhibitory M2 muscarinic receptor dysfunction. Interestingly, the TLR agonists independently caused non-M2-dependent AHR. These data confirm the therapeutic antiviral potential of TLR agonists, while suggesting that virus inhibition may be insufficient to prevent virus-induced airway pathophysiology. Furthermore, TLR agonists independently cause AHR, albeit through a distinctly differentmechanismfrom that of parainfluenza virus.",
keywords = "Airway hyperreactivity, Muscarinic receptor, Parainfluenza virus, Toll-like receptor",
author = "Matthew Drake and Evans, {Scott E.} and Dickey, {Burton F.} and Allison Fryer and David Jacoby",
year = "2013",
month = "6",
doi = "10.1165/rcmb.2012-0498OC",
language = "English (US)",
volume = "48",
pages = "790--796",
journal = "American Journal of Respiratory Cell and Molecular Biology",
issn = "1044-1549",
publisher = "American Thoracic Society",
number = "6",

}

TY - JOUR

T1 - Toll-like receptor-2/6 and toll-like receptor-9 agonists suppress viral replication but not airway hyperreactivity in guinea pigs

AU - Drake, Matthew

AU - Evans, Scott E.

AU - Dickey, Burton F.

AU - Fryer, Allison

AU - Jacoby, David

PY - 2013/6

Y1 - 2013/6

N2 - Respiratory virus infections cause airway hyperreactivity (AHR). Preventative strategies for virus-induced AHR remain limited. Toll-like receptors (TLRs) have been suggested as a therapeutic target because of their central role in triggering antiviral immune responses. Previous studies showed that concurrent treatment with TLR2/6 and TLR9 agonists reduced lethality and the microbial burden in murine models of bacterial and viral pneumonia. This study investigated the effects of TLR2/6 and TLR9 agonist pretreatment on parainfluenza virus pneumonia and virus-induced AHR in guinea pigs in vivo. Synthetic TLR2/6 lipopeptide agonist Pam2CSK4 and Class C oligodeoxynucleotide TLR9 agonist ODN2395, administered in combination 24 hours before virus infection, significantly reduced viral replication in the lung. Despite a fivefold reduction in viral titers, concurrent TLR2/6 and TLR9 agonist pretreatment did not prevent virus-induced AHR or virus-induced inhibitory M2 muscarinic receptor dysfunction. Interestingly, the TLR agonists independently caused non-M2-dependent AHR. These data confirm the therapeutic antiviral potential of TLR agonists, while suggesting that virus inhibition may be insufficient to prevent virus-induced airway pathophysiology. Furthermore, TLR agonists independently cause AHR, albeit through a distinctly differentmechanismfrom that of parainfluenza virus.

AB - Respiratory virus infections cause airway hyperreactivity (AHR). Preventative strategies for virus-induced AHR remain limited. Toll-like receptors (TLRs) have been suggested as a therapeutic target because of their central role in triggering antiviral immune responses. Previous studies showed that concurrent treatment with TLR2/6 and TLR9 agonists reduced lethality and the microbial burden in murine models of bacterial and viral pneumonia. This study investigated the effects of TLR2/6 and TLR9 agonist pretreatment on parainfluenza virus pneumonia and virus-induced AHR in guinea pigs in vivo. Synthetic TLR2/6 lipopeptide agonist Pam2CSK4 and Class C oligodeoxynucleotide TLR9 agonist ODN2395, administered in combination 24 hours before virus infection, significantly reduced viral replication in the lung. Despite a fivefold reduction in viral titers, concurrent TLR2/6 and TLR9 agonist pretreatment did not prevent virus-induced AHR or virus-induced inhibitory M2 muscarinic receptor dysfunction. Interestingly, the TLR agonists independently caused non-M2-dependent AHR. These data confirm the therapeutic antiviral potential of TLR agonists, while suggesting that virus inhibition may be insufficient to prevent virus-induced airway pathophysiology. Furthermore, TLR agonists independently cause AHR, albeit through a distinctly differentmechanismfrom that of parainfluenza virus.

KW - Airway hyperreactivity

KW - Muscarinic receptor

KW - Parainfluenza virus

KW - Toll-like receptor

UR - http://www.scopus.com/inward/record.url?scp=84881008524&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84881008524&partnerID=8YFLogxK

U2 - 10.1165/rcmb.2012-0498OC

DO - 10.1165/rcmb.2012-0498OC

M3 - Article

C2 - 23449736

AN - SCOPUS:84881008524

VL - 48

SP - 790

EP - 796

JO - American Journal of Respiratory Cell and Molecular Biology

JF - American Journal of Respiratory Cell and Molecular Biology

SN - 1044-1549

IS - 6

ER -